MediWound Receives $112M BARDA Contract

October 1, 2015 | The wound and burn care solutions provider MediWound has been awarded a $112 million contract by the US Biomedical Advanced Research & Development Authority (BARDA). As part of the deal, which extends over a five year period, MediWound’s NexoBrid, a bandage that removes dead tissue cells from medium to severe burn wounds, will be applied by American authorities in emergency situations. The deal also includes a $24 million push from BARDA to receive expedited Food & Drug Administration approval for NexoBrid’s use in the US. MediWound was founded in 2001 and is based out of Yavne, Israel.